心衰是心脏病患者常见的危重症，是年龄 > 65 岁患者住院的主要原因。而 BNP 作为目前心衰诊疗中应用最广泛的生物标志物，不仅可以预测心衰的发生，还可以用于心衰的诊断、治疗及预后评估。1BNP 的定义和作用钠尿肽（natriuretic ...

Among cardiovascular deaths, sudden death and heart failure death are the leading cardiac modes of death in HFPEF clinical trials. Compared with HFREF, the proportions of cardiovascular deaths ...

目前SalubrisBio提交有关申请已届满30日，根据有关规定可以开展JK07慢性心力衰竭的HFrEF和HFpEF适应症的II期临床研究。 每日经济新闻 ...

Recent pre-clinical studies in mice show that glucagon blockers can improve heart function in HFpEF, a type of heart failure.

Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Cytokinetics (CYTK – Research Report). The associated price ...

Distinct characteristics of heart failure (HF), relative to ejection fraction, that could be used to improve HF risk prediction models have been characterized in a new study by Lee and colleagues.

That indication has helped drive quarterly sales of the drug above the $1 billion threshold, but its growth has been threatened by approvals of Jardiance (empagliflozin) for both HFrEF and HFpEF ...

There is strong evidence for the use of MRAs to improve cardiovascular outcomes in patients with HFrEF, but their benefits in ...

Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM ...

Forxiga is so far only cleared for HFrEF in the US and Europe, although AZ is testing Farxiga for HFpEF as well. Its phase 3 trial – called DELIVER – is expected generate results in the coming ...